Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J. Moschos(University of North Carolina at Chapel Hill), Keith T. Flaherty(Massachusetts General Hospital)JCI InsightFebruary 21, 201810.1172/jci.insight.92352Cited by 147SaveCiteExport RISWatch citationsRelated PapersFirst‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors|Cancer|2017|34